title: [Substrate metabolism in untreated and treated thyrotoxicosis].
abstract: Accelerated metabolism is a hallmark of thyrotoxicosis, but the underlying biochemical mechanisms are incompletely understood. In order to elucidate these metabolic events further, we studied 12 patients with newly diagnosed diffuse (10 patients) or nodular (two patients) toxic goitre (ten women, two men; age 42.8 +/- 3.2 yr; BMI: 21.6 +/- 0.7 kg/m2) before ("TOX") and after ("TRE") 11.2 +/- 1.0 weeks treatment with methimazole and compared these patients to a control group ("CTR") of 11 subjects (nine women, two men; age 40.5 +/- 3.9 yr; BMI 22.5 +/- 1.0 kg/m2). All were studied for three hours in the basal state, using indirect calorimetry, isotope dilution for measurement of glucose turnover and the forearm technique for assessment of muscle metabolism. Prior to treatment patients with thyrotoxicosis were characterized by: Increased (p < 0.05) levels of T3 (3.75 +/- 0.23 [TOX], 1.89 +/- 0.08 [TRE] and 1.75 +/- 0.11 [CTR] nmol/l), resting energy expenditure (130.5 +/- 3.5 [TOX], 107.7 +/- 2.7 [TRE] and 106.3 +/- 3.1 [CTR] percent of predicted), protein oxidation (0.67 +/- 0.03 [TOX], 0.54 +/- 0.06 [TRE] and 0.46 +/- 0.05 [CTR] mg/kg/min), lipid oxidation (1.34 +/- 0.08 [TOX], 1.00 +/- 0.06 [TRE] and 1.02 +/- 0.04 [CTR] mg/kg/min), endogenous glucose production (2.51 +/- 0.13 [TOX], 1.86 +/- 0.12 [TRE] and 1.85 +/- 0.12 [CTR] mg/kg/min), non-oxidative glucose turnover (1.28 +/- 0.16 [TOX], 0.75 +/- 0.18 [TRE] and 0.71 +/- 0.11 [CTR] mg/kg/min) and a 50% increase in total forearm blood flow. Glucose oxidation (1.23 +/- 0.09 [TOX], 1.13 +/- 0.10 [TRE] and 1.13 +/- 0.09 [CTR] mg/kg/min), exchange of substrates in the muscles of the forearm and circulating levels of insulin, C-peptide, growth hormone or glucagon were not influenced by hyperthyroidism. Propranolol (20 mg thrice daily) given to seven of the patients for two days did not affect circulating levels of thyroid hormones, energy expenditure or glucose turnover rates. These results suggest that all major fuel sources contribute to the hypermetabolism of thyrotoxicosis and that augmented non-oxidative glucose metabolism may further aggravate the condition. All abnormalities recede with medical treatment of the disease.
authors.affiliation: Arhus Universitetshospital, Arhus Kommunehospital, medicinsk afdeling M.
authors.forename: N
authors.initials: N
authors.lastname: Møller
authors.forename: K Y
authors.initials: KY
authors.lastname: Hove
authors.forename: S
authors.initials: S
authors.lastname: Nielsen
authors.forename: B
authors.initials: B
authors.lastname: Nyholm
authors.forename: N K
authors.initials: NK
authors.lastname: Pørksen
authors.forename: J
authors.initials: J
authors.lastname: Weeke
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D004734:Energy Metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism; D006042:Goiter / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D006044:Goiter, Nodular / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D015219:Substrate Cycling; D013963:Thyroid Hormones / Q000097:blood; D013971:Thyrotoxicosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D013956:Antithyroid Agents; D013963:Thyroid Hormones; D008713:Methimazole; D005947:Glucose
vernacular_title: Substratomsaetning ved tyreotoksikose før og efter medicinsk behandling.